ISTA Pharmaceuticals to Present at the Bank of America 2007 Health Care Conference
Posted on: Thursday, 24 May 2007, 09:00 CDT
IRVINE, Calif., May 24 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. , today announced it will present at the Bank of America 2007 Health Care Conference at 4:40 p.m. Pacific Daylight Time on Wednesday, May 30, at the Four Seasons Hotel in Las Vegas.
ISTA's President and Chief Executive Officer, Vicente Anido, Jr., Ph.D., will provide an update on the Company's commercial and clinical progress. To access the live audio broadcast or the subsequent archived recording log onto http://www.istavision.com/. Please connect to the website several minutes prior to the start of the conference call to ensure adequate time for any software download that may be necessary.
ABOUT ISTA PHARMACEUTICALS
ISTA Pharmaceuticals is an ophthalmic pharmaceutical company. ISTA's products and product candidates addressing the $3.2 billion U.S. prescription ophthalmic industry include therapies for inflammation, ocular pain, glaucoma, allergy, dry eye, and vitreous hemorrhage. The Company currently markets three products and is developing a strong product pipeline to fuel future growth and market share. The Company's product development and commercialization strategy is to launch a new product every 12 to 18 months, thereby continuing its growth to become the leading niche ophthalmic pharmaceutical company in the U.S. For additional information regarding ISTA, please visit ISTA Pharmaceuticals' website at http://www.istavision.com/.
ISTA Pharmaceuticals
CONTACT: Vince Anido, +1-949-788-5311, or vanido@istavision.com, orLauren Silvernail, +1-949-788-5302, or lsilvernail@istavision.com, both ofISTA Pharmaceuticals; or Media, Jason Farber, jfarber@burnsmc.com, orInvestors, Juliane Snowden-Andrew, jsnowden-andrew@burnsmc.com,+1-212-213-0006, both of Burns McClellan for ISTA Pharmaceuticals
Web site: http://www.istavision.com/
Source: PRNewswire-FirstCall
Related Articles
- ISTA Pharmaceuticals Announces Positive Preliminary Phase 3 Clinical Results to Support sNDA Filing for Once-Daily Xibrom(TM) 0.09%
- ISTA Pharmaceuticals' New Drug Application for Bepreve(TM) Accepted for Review by U.S. Food and Drug Administration
- ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom(TM) 0.09%
- ISTA Pharmaceuticals to Present at the Lazard Capital Markets Healthcare Conference
- ISTA Pharmaceuticals Announces Conference Call and Webcast of Third Quarter 2007 Financial Results
- ISTA Pharmaceuticals to Present at Two Upcoming Investor Conferences
- ISTA Pharmaceuticals Announces Statistically Significant Preliminary Results From Its U.S. Phase II/III Clinical Study Of Bepotastine
- ISTA Pharmaceuticals to Present at the SIGnificant Investment Options in Healthcare Conference
- ISTA Pharmaceuticals to Present at the Lazard Capital Markets Third Annual Life Sciences Conference
 |
 |
User Comments (0)
RSS Feeds